MA46988A1 - Liquid formulation of anti-tnf alpha antibodies - Google Patents

Liquid formulation of anti-tnf alpha antibodies

Info

Publication number
MA46988A1
MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
Authority
MA
Morocco
Prior art keywords
liquid formulation
tnf alpha
alpha antibodies
antibodies
tnf
Prior art date
Application number
MA46988A
Other languages
French (fr)
Inventor
So Ra Yun
Youn Kyung Ko
Jineon So
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA46988(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA46988A1 publication Critical patent/MA46988A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Abstract

La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.The present invention relates to a liquid formulation of an anti-tnf alpha antibody, in particular adalimumab.

MA46988A 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies MA46988A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170033188 2017-03-16
PCT/KR2018/003097 WO2018169348A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibody

Publications (1)

Publication Number Publication Date
MA46988A1 true MA46988A1 (en) 2020-06-30

Family

ID=63522490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46988A MA46988A1 (en) 2017-03-16 2018-03-16 Liquid formulation of anti-tnf alpha antibodies

Country Status (15)

Country Link
JP (2) JP7109849B2 (en)
KR (2) KR20180106974A (en)
CN (1) CN110621303A (en)
AU (1) AU2018236651B2 (en)
BR (1) BR112019019162A2 (en)
CO (1) CO2019010860A2 (en)
MA (1) MA46988A1 (en)
MX (1) MX2019010895A (en)
MY (1) MY197202A (en)
NZ (1) NZ757965A (en)
PH (1) PH12019502075A1 (en)
RU (1) RU2756619C2 (en)
UA (1) UA123847C2 (en)
WO (1) WO2018169348A1 (en)
ZA (1) ZA201906696B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA55033A (en) 2019-02-18 2021-12-29 Lilly Co Eli THERAPEUTIC ANTIBODY FORMULATION
TW202102260A (en) * 2019-03-21 2021-01-16 美商再生元醫藥公司 Stabilized formulations containing anti-il-33 antibodies
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2815689C (en) * 2010-11-11 2016-11-22 Abbvie Biotechnology Ltd. Improved high concentration anti-tnf.alpha. antibody liquid formulations
UY34105A (en) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd STABLE LIQUID FORMULATION OF ETANERCEPT
EP3412310B1 (en) * 2012-03-07 2022-09-07 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies
KR102238677B1 (en) 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 Stable aqueous formulations of adalimumab
RU2015130100A (en) 2013-01-24 2017-03-03 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед TNF-alpha antigen binding proteins
CA2906101A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2015134406A1 (en) 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
US10688187B2 (en) 2014-04-02 2020-06-23 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
ES2600488T3 (en) * 2014-05-23 2017-02-09 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (en) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Pharmaceutical anti-tnfalpha antibody formulation
TW201636047A (en) * 2015-01-28 2016-10-16 麥博賽恩斯有限公司 Pharmaceutical formulations for anti-TNF-alpha antibodies
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody

Also Published As

Publication number Publication date
MX2019010895A (en) 2019-11-05
KR20200096472A (en) 2020-08-12
RU2019130728A3 (en) 2021-04-16
UA123847C2 (en) 2021-06-09
AU2018236651B2 (en) 2020-12-10
PH12019502075A1 (en) 2020-09-14
RU2019130728A (en) 2021-04-16
CO2019010860A2 (en) 2020-01-17
CN110621303A (en) 2019-12-27
JP2022097600A (en) 2022-06-30
KR102342292B1 (en) 2021-12-24
JP7109849B2 (en) 2022-08-01
RU2756619C2 (en) 2021-10-04
KR20180106974A (en) 2018-10-01
AU2018236651A1 (en) 2019-10-31
ZA201906696B (en) 2020-08-26
BR112019019162A2 (en) 2020-04-14
NZ757965A (en) 2022-07-01
MY197202A (en) 2023-05-31
WO2018169348A1 (en) 2018-09-20
JP2020510079A (en) 2020-04-02

Similar Documents

Publication Publication Date Title
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
CL2018003520A1 (en) Anti-b7-h3 antibodies and antibody and drug conjugates.
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
CL2022000027A1 (en) PCSK9 antagonist compounds. (Application divisional 202003257).
MX2018012648A (en) Antibody-containing preparation.
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
MA43603A1 (en) Chimeric receptors and methods of use
MA40576B1 (en) Anti-her2 antibodies and immunoconjugates
MA44594B1 (en) Anti-ctla-4 Antibodies and Methods of Use thereof
MA45450B1 (en) Anti-cd19 antibody formulations
MA38632A1 (en) Anti-transferrin receptor antibody and methods of use
MA38322A1 (en) Anti-il-17a antibodies and their use in the treatment of autoimmune and inflammatory disorders
IN2012DN05237A (en)
MA35009B1 (en) ANTI-SCLERROTIN ANTIBODY CRYSTALS AND FORMULATIONS THEREOF
MA38828A1 (en) Antibodies to plasminogen activator inhibitor type 1 (pai-1) and their uses
EA201991701A1 (en) COMPOSITION BASED ON MONOCLONAL ANTIBODY TO RSV
CO6270369A2 (en) NEW SPECIFIC ANTIBODIES OF BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC OR DRUG AGENTS
MA37946A1 (en) Treatment of rheumatoid arthritis
MA44645B1 (en) Combined treatment of an anti-cd20 antibody with a bcl-2 inhibitor and an mdm2 inhibitor
MX2022001146A (en) Anti-pvrig antibodies formulations and uses thereof.
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies
MA47221A1 (en) Monoclonal antibody to pd-l1
MA38413A1 (en) Pan-elr + cxc chemokine antibody
EA202192405A1 (en) COMPOSITIONS OF ANTIBODIES AGAINST IL-36R
EA201992027A1 (en) WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1